Clinical Trials Browser

Phase 1 × Metastatic Castration-resistant Prostate Cancer (mCRPC) × pembrolizumab × Clear all

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Phase 1 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)